Monographs on ARV and hepatitis medicines in The International Pharmacopoeia
|
|
- Eric Matthews
- 5 years ago
- Views:
Transcription
1 Monographs on ARV and hepatitis medicines in The International Pharmacopoeia Technologies, Standards and Norms 1
2 The International Pharmacopoeia contains analytical methods and specifications for active pharmaceutical ingredients (API) finished pharmaceutical products radiopharmaceuticals focuses on medicines Model List of Essential Medicines Invitations to submit EOI for product evaluation to PQTm WHO/UN specific disease programmes 2
3 The International Pharmacopoeia main areas of work medicines for maternal, newborn, child and adolescent health antimalarial medicines antiviral medicines including antiretrovirals antituberculosis medicines medicines for tropical diseases part of WHO normative work based on the decision of the WHO Expert Committee on Specifications for Pharmaceutical Preparations (ECSPP) 3
4 The International Pharmacopoeia applies current international standards comply with harmonized regulatory standards focus on technical aspects most relevant for developing countries Ph.Int. aims at global applicability of its methods/specifications for complex, technically demanding methods less sophisticated tests are given as an alternative, if equally satisfying rational use of International Chemical Reference substances (ICRS) in situ preparation of impurities for identification purposes quantification of impurities preferably by comparing their responses with the response of the parent compound in a diluted sample solution (together with the establishment of correction factors) 4
5 International Chemical Reference Substances (ICRS) primary reference standards established by European Directorate for the Quality of Medicines & HealthCare (EDQM) under the authority of WHO Expert Committee on Specifications for Pharmaceutical Preparations 5
6 Antiviral medicines including antiretrovirals 34 monographs on antiviral medicines Abacavir oral solution, Abacavir tablets, Aciclovir for injection, Aciclovir tablets, Atazanavir capsules, Didanosine oral powder, Didanosine tablets, Paediatric didanosine liquid for oral use, Efavirenz capsules, Efavirenz, emtricitabine and tenofovir tablets, Efavirenz oral solution, Efavirenz tablets, Emtricitabine and tenofovir tablets, Emtricitabine capsules, Indinavir capsules, Lamivudine oral solution, Lamivudine tablets, Lopinavir and ritonavir tablets, Nelfinavir mesilate oral powder, Nelfinavir mesilate tablets, Nevirapine oral suspension, Nevirapine tablets, Oseltamivir capsules, Ritonavir tablets, Saquinavir mesilate capsules, Saquinavir tablets, Stavudine capsules, Tenofovir tablets, Zidovudine and lamivudine tablets, Zidovudine capsules, Zidovudine intravenous infusion, Zidovudine, lamivudine and abacavir tablets, Zidovudine, lamivudine and nevirapine tablets, Zidovudine oral solution 6
7 Work Plan 2015/2016 the development of new monographs follows our priority setting procedures: monographs for essential medicines listed in EOI 12th Invitation HIV/AIDS, hepatitis B/C medicines (September 2014) that have not yet been subject to a monograph published by another major pharmacopoeia USP 38; IP 2014 (incl. Addendum 2015), BP 2015, CP 2010, JP 16 will be developed with HIGH PRIORITY result of the survey performed in antiviral medicines (incl. antiretrovirals) were identified for future elaboration with high priority 7
8 Work Plan 2015/2016 Monographs proposed for future elaboration ABACAVIR, EFAVIRENZ AND LAMIVUDINE TABLETS ABACAVIR, LAMIVUDINE AND NEVIRAPINE DISPERSIBLE TABLETS ATAZANAVIR AND RITONAVIR TABLETS DOLUTEGRAVIR TABLETS EFAVIRENZ, LAMIVUDINE AND TENOFOVIR TABLETS ENTECAVIR ORAL SOLUTION ENTECAVIR TABLETS RALTEGRAVIR TABLETS RIBAVIRIN SYRUP RITONAVIR ORAL SOLUTION SIMEPREVIR CAPSULE SOFOSBUVIR TABLETS TERIZIDONE CAPSULES TERIZIDONE TABLETS ETRAVIRINE TABLETS ZANAMIVIR POWDER FOR INHALATION LAMIVUDINE AND TENOFOVIR TABLETS 8
9 Benefits of Public Standards / Ph. Int. public standards facilitate the production, registration, quality control and procurement of medicines allow for an independent judgment on the quality of medicines easy reference to acceptable quality standards (specifications, test methods and reference substances) manufacturer has to demonstrate suitability of the tests regulatory authorities have to approve the specifications basis for regional/international harmonization represent reference tests in case of doubt or dispute applicable worldwide (The International Pharmacopoeia) 9
10 How to participate in the work of The International Pharmacopoeia? comments are welcome on monographs and general texts under public consultation already published monographs and general texts web site with our current projects: donations are welcome SRA approved test procedures and specifications product samples to verify test procedures to back up specifications candidate material to establish ICRS 10
11 Quality Assurance of Pharmaceuticals guidelines development production distribution inspection quality control other regulatory affaires 11
12 Thank you very much for your kind attention!
1. PROCEDURE FOR THIS INVITATION TO EOI 2. APIS INCLUDED IN THE 14TH INVITATION. Guidance Document 11 April 2017
To support national and global efforts to increase access to and the affordability of care and treatment of HIV/AIDS, hepatitis B and C, tuberculosis, malaria, neglected tropical diseases, influenza, diarrhoea
More informationThe International Pharmacopoeia - Overview
The International Pharmacopoeia - Overview Caroline Mendy - Technical Officer Quality Assurance and Safety: Medicines World Health Organization 1 The International Pharmacopoeia Ph. Int. Scope WHO Consultative
More informationCURRENT WORK PLAN New monographs for inclusion in The International Pharmacopoeia and revision of related monographs
page 1 CURRENT WORK PLAN New monographs for inclusion in The International Pharmacopoeia and revision of related monographs 2011 The following categories are included in this work programme: 1. Medicines
More informationUpdate on the Medicines Patent Pool
Update on the Medicines Patent Pool Sandeep Juneja November 06, 2012 How the Pool works* The Pool is an innovative licensing mechanism for HIV medicines Licensors Patents Feedback Market Impact Product
More informationInvitation to Manufacturers 16 August 2017
Invitation to Manufacturers 16 August 2017 Manufacturers of Antiretroviral (HIV/AIDS), Antihepatitis B and C, Antituberculosis and Antimalarial medicines Are Invited to Submit An Expression of Interest
More information1. Procedure for this Invitation to EOI. 2. Medicinal products included on the 14 th Invitation. Guidance Document 14 May 2016
To support national and global efforts to increase access to and the affordability of HIV/AIDS-related care and treatment together with UNICEF, UNAIDS and UNITAID, invite applicants for selected pharmaceutical
More informationPHARMACOKINETICS OF ANTIRETROVIRAL AND ANTI-HCV AGENTS
8. PHARMACOKINETICS OF ANTIRETROVIRAL AND ANTI-HCV AGENTS David Burger José Moltó Table 8.1a: INFLUENCE OF FOOD ON ABSORPTION (AREA UNDER THE CURVE) OF ANTIRETROVIRAL AGENTS NUCLEOSIDE ANALOGUES NtRTI
More informationThe Medicines Patent Pool: An Update. June 2012 Geneva, Switzerland
The Medicines Patent Pool: An Update June 2012 Geneva, Switzerland The Medicines Patent Pool Royalties Licensor Licensor Patents Generics versions of existing compounds Licensor Licensor Patents Patents
More informationHIV MEDICATIONS AT A GLANCE. Atripla 600/200/300 mg tablet tablet daily. Complera 200/25/300 mg tablet tablet daily
HIV MEDICATIONS AT A GLANCE Generic Name Trade Name Strength DIN Usual Dosage Single Tablet Regimen (STR) Products Efavirenz/ Emtricitabine/ rilpivirine/ elvitegravir/ cobicistat/ alafenamide Emtricitabine/
More informationWOMENS INTERAGENCY HIV STUDY ANTIRETROVIRAL DOSAGE FORM SECTION A. GENERAL INFORMATION
WOMENS INTERAGENCY HIV STUDY ANTIRETROVIRAL DOSAGE FORM SECTION A. GENERAL INFORMATION A1. PARTICIPANT ID: ENTER NUMBER HERE - - - ONLY IF ID LABEL IS NOT AVAILABLE A2. VISIT #: A3. VERSION DATE: 1 0 /
More informationHIV in the Brain MANAGING COMORBIDITIES IN PATIENTS WITH HIV
HIV in the Brain MANAGING COMORBIDITIES IN PATIENTS WITH HIV Shibani S. Mukerji MD, PhD Massachusetts General Hospital, Division of Immunologic, Inflammatory and Infectious Neurological Diseases Dana-Farber
More information5 Infections. To be used in conjunction with NICE guidance, The British National Formulary for adults and/or children and
5 Infections To be used in conjunction with NICE guidance, The British National Formulary for adults and/or children and Southend University Hospital, Antibiotic Guidelines Index 5.1 Antibacterial drugs
More informationIndustry Data Request
Industry Data Request Purpose: reported data will be used internally to populate patient forecasting models that are used for business planning. Business planning includes stock requirement forecasts,
More informationTORONTO GENERAL HOSPITAL HIV AMBULATORY CARE ROTATION
TGH - ambulatory rotation page 1 of 5 TORONTO GENERAL HOSPITAL HIV AMBULATORY CARE ROTATION SITE: Immunodeficiency Clinic, Toronto General Hospital, University Health Network Location: 13 th floor, Norman
More informationTHE HIV LIFE CYCLE. Understanding How Antiretroviral Medications Work
THE HIV LIFE CYCLE Understanding How Antiretroviral Medications Work DEFINITIONS Host: The animal or cell that another organism lives in. In HIV human CD4 T-cells are the host for HIV. Nucleus: The core
More informationPrequalification Team Medicines (PQTm) Bioequivalence Assessment Update. Dr. John Gordon
Prequalification Team Medicines (PQTm) Bioequivalence Assessment Update Dr. John Gordon 1 Overview Bioequivalence (BE) guideline updates Notes on bioequivalence study design Product specific guidance Comparator
More informationThe International Pharmacopoeia
The International Pharmacopoeia Dr Sabine Kopp Quality Assurance and Safety: Medicines World Health Organization 2 The International Pharmacopoeia Int.Ph. 1. Introduction 2. Int. Ph. - historical overview
More informationTopics covered by the talk
04/02/2016 Finished product monographs containing chemically defined active substances Dr Dirk Leutner Scientific Officer, European Pharmacopoeia Department European Directorate for the Quality of Medicines
More informationBritish HIV Association Guidelines for the Management of Hepatitis Viruses in Adults Infected with HIV 2013 Appendix 2
British HIV Association Guidelines for the Management of Hepatitis Viruses in Adults Infected with HIV 2013 Appendix 2 Systematic literature search 2.1 Questions and PICO criteria Data bases: Medline,
More informationCentral Nervous System Penetration of ARVs: Does it Matter?
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Central Nervous System Penetration of ARVs: Does it Matter? Christina M. Marra, MD Neurology and Medicine (Infectious Diseases) University of Washington 15
More informationAntiretroviral Dosing in Renal Impairment
Protease Inhibitors (PIs) Atazanavir Reyataz hard capsules 300 mg once daily taken with ritonavir 100 mg once daily No dosage adjustment is needed for atazanavir in renal impairment Atazanavir use in haemodialysis
More informationThe use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines
The use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines I. Boucoiran, T. Lee, K. Tulloch, L. Sauve, L. Samson, J. Brophy, M. Boucher and D. Money For and
More informationContinuing Education for Pharmacy Technicians
Continuing Education for Pharmacy Technicians HIV/AIDS TREATMENT Michael Denaburg, Pharm.D. Birmingham, AL Objectives: 1. Identify drugs and drug classes currently used in the management of HIV infected
More informationREIMBURSEMENT STATUS OF HIV MEDICATIONS IN ONTARIO
REIMBURSEMENT STATUS OF HIV MEDICATIONS IN ONTARIO Ont. Drug Distr. Ontario Drug Benefit/Trillium: Other Formulary (F/A) Limited Use (Section 16) Antiretrovirals AZT 100 mg capsules NRTIs (single): Abacavir,
More informationPRAC recommendations on signals
3 April 2018 1 EMA/PRAC/136563/2018 Pharmacovigilance Risk Assessment Committee (PRAC) Adopted at the 5-8 March 2018 PRAC meeting This document provides an overview of the recommendations adopted by the
More informationThe Hospitalized HIV+ Patient
The Hospitalized HIV+ Patient Danny Toub MD dannyt@srheathcenters.org October 8, 2012 Santa Rosa Family Medicine Residency List 3 ways of risk-stratifying known or suspected HIV+ inpatients Perform differential
More informationDrug Treatment Program Update
Drug Treatment Program Update As of March 211 Drug Treatment Program Update A key component of the Centre s mandate is to monitor the impact of HIV/AIDS on British Columbia. The Centre provides essential
More informationChapter 5 ~ Infections
Chapter 5 ~ Infections: Special Section 1 of 6 Chapter 5 ~ Infections Please refer to The Hillingdon Hospitals NHS Trust Antibiotic Guidelines, Policy number 233, and Surgical Prophylaxis Policy, Policy
More informationPOST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV
POST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV DISCLOSURE Relevant relationships with commercial entities none Potential for conflicts of interest within this presentation none
More informationSection 6: Treatment of Hepatitis C virus (HCV)
Section 6: Treatment of Hepatitis C virus (HCV) Dr. Niklas Luhmann (Médecins du Monde) Training Hepatitis C and HR for PWUD, 9 th -13 th May 2016, Hanoi, Vietnam Learning objective of the session: understanding
More informationHIV associated CNS disease in the era of HAART
HIV associated CNS disease in the era of HAART CSF/CNS penetration and efficacy Acknowledgements Peter Portegies Department of Neurology, AMC Mark van der Valk Department of Internal Medicine/Infectious
More informationEDQM and European Pharmacopoeia: State-of-the-art Science for Tomorrow s Medicines
EDQM and European Pharmacopoeia: State-of-the-art Science for Tomorrow s Medicines International Conference organised by the European Directorate for the Quality of Medicines & HealthCare (EDQM), Council
More informationHIV basics. Katya Calvo Medical Director of Antimicrobial Stewardship
HIV basics Katya Calvo Medical Director of Antimicrobial Stewardship Learning Objectives 1. Review of HIV epidemiology worldwide and locally 2. Review of recommendations on whom to screen 3. Work up of
More informationGPRM - Global Price Reporting Mechanism November Transaction prices for Antiretroviral Medicines and HIV Diagnostics from 2008 to October 2009
Transaction prices for Antiretroviral Medicines and HIV Diagnostics from 2008 to October 2009 A summary report from the Global Price Reporting Mechanism Contents Abbreviations. 5 Table 1 : of first-line
More informationSecond-Line Therapy NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Second-Line Therapy David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, Division of Infectious Diseases University of Washington Presentation
More informationPharmacological considerations on the use of ARVs in pregnancy
Pharmacological considerations on the use of ARVs in pregnancy 11 th Residential Course on Clinical Pharmacology of Antiretrovirals Torino, 20-22 January 2016 Prof. David Burger, PharmD, PhD david.burger@radboudumc.nl
More information0.14 ( 0.053%) UNAIDS 10% (94) ( ) (73-94/6 ) 8,920
0.14 UNAIDS 0.053% 2 250 60 10% 94 73 20 73-94/6 8,920 12 43 Public Health Service Task Force Recommendations 5-10% for Use of Antiretroviral Drugs in 10-20% Pregnant HIV-1-Infected Women for Maternal
More informationIndustry Request Integrase Inhibitors
Industry Request Integrase Inhibitors The objective of this request is to describe and understand the temporal changes in the prescribing practices of Integrese Inibitors (II) in AHOD cohort between 1/1/
More informationARVs on an Empty Stomach: Food Interaction Studies in a resource Limited Setting
ARVs on an Empty Stomach: Food Interaction Studies in a resource Limited Setting Dr. Andrew D Kambugu, FRCP (UK) Infectious Diseases Institute, Makerere University Outline of Discussion Key Definitions
More informationWOMEN'S INTERAGENCY HIV STUDY METABOLIC STUDY: MS01 SPECIMEN COLLECTION FORM
WOMEN'S INTERAGENCY HIV STUDY METABOLIC STUDY: MS01 SPECIMEN COLLECTION FORM ID LABEL HERE ---> VERSION DATE 10/01/07 - - - VISIT #: FORM COMPLETED BY: A1. DATE OF BLOOD DRAW: / / M D Y A2. Do you take
More informationDistribution and Effectiveness of Antiretrovirals in the Central Nervous System
Distribution and Effectiveness of Antiretrovirals in the Central Nervous System Scott Letendre, MD Associate Professor of Medicine HIV Neurobehavioral Research Center and Antiviral Research Center University
More informationPediatric Antiretroviral Resistance Challenges
Pediatric Antiretroviral Resistance Challenges Thanyawee Puthanakit, MD The HIVNAT, Thai Red Cross AIDS research Center The Research Institute for Health Science, Chiang Mai University Outline The burden
More informationTreatment of respiratory virus infection Influenza A & B Respiratory Syncytial Virus (RSV)
Treatment of respiratory virus infection Influenza A & B Respiratory Syncytial Virus (RSV) Amantadine and Rimantadine Use is limited to Influenza A infection. Very effective in preventing infection if
More informationAntiretrovial Crushable/Liquid Formulation Chart
Antiretrovial Crushable/Liquid Formulation Chart Eliza Dollard, PharmD; Nafeesa Chin-Beckford, PharmD; Laura Aragon, PharmD Last Updated: 04/2016 Agent How Supplied Crushable Status **Products listed in
More informationREVIEW No Assessment of safety a. Have all relevant studies on safety been included Yes X No (if no, please provide reference and information)
Expert peer review on application for addition of fixed dose combination formulations of antiretroviral medications in the EML (Adults) REVIEW No. 2 Abacavir + lamivudine (ABC+ 3TC) Tablet (dispersible):
More informationFIXED DOSE COMBINATION: CLINICAL & PHARMACEUTICAL PERSPECTIVES
FIXED DOSE COMBINATION: CLINICAL & PHARMACEUTICAL PERSPECTIVES Cape Winelands Anova Conference 2013 Worcester Lindsay Wilson 3 June 2013 What is a fixed dose combination [FDC]? Pharmaceutical formulation
More informationSUMMARY MEETING REPORT. Annual stakeholders and partners meeting AIDS Medicines and Diagnostics Service. Geneva, 7 8 May 2013
SUMMARY MEETING REPORT Annual stakeholders and partners meeting AIDS Medicines and Diagnostics Service Geneva, 7 8 May 2013 Department of HIV/AIDS HIV Technologies and Commodities May 2013 WHO/HIV/2013.6
More informationDaclatasvir (Daklinza ) Drug Interactions with HIV Medications
Daclatasvir/Sofosbuvir (Daklinza /Sovaldi TM ) Drug Interactions A Quick Guide for Clinicians April 2017 John J Faragon, PharmD, BCPS, AAHIVP Mechanism of Action and Route of Metabolism for Daclatasvir
More informationProduct Characteristics and Product Information Links between Quality and Clinical
Product Characteristics and Product Information Links between Quality and Clinical Regine Lehnert 8th Annual Prequalification Assessment Training (Quality), Copenhagen, 16-18th May 2016 A Good Medicinal
More informationSimplifying HIV Treatment Now and in the Future
Simplifying HIV Treatment Now and in the Future David M. Hachey, Pharm.D., AAHIVP Professor Idaho State University Department of Family Medicine Nothing Disclosure 1 Objectives List current first line
More informationSelected Issues in HIV Clinical Trials
Selected Issues in HIV Clinical Trials Judith S. Currier, M.D., MSc Professor of Medicine Division of Infectious Diseases University of California, Los Angeles Issues Evolving Global and Domestic Epidemic
More informationHIV DISEASE! Neurobehavioral! Neuromedical. Igor Grant, MD, FRCP(C) Director HIV Neurobehavioral Research Program University of California, San Diego
Igor Grant, MD, FRCP(C) Director HIV Neurobehavioral Research Program University of California, San Diego HIV DISEASE! Neuromedical Neurobehavioral! HIV Neurobehavioral Disturbances HIV Associated Neurocognitive
More informationWorld Health Organization 2007
World Health Organization 2007 All rights reserved. The document may not be reviewed, abstracted, quoted, reproduced, transmitted, distributed, translated or adapted, in part or in whole, in any form or
More informationGeneral concepts in the Ph. Eur.: theory and rationale
General concepts in the Ph. Eur.: theory and rationale Cathie VIELLE Head of European Pharmacopoeia Department, EDQM / CoE 1 The structure of the Ph. Eur. General monographs Dosage form monographs General
More informationToo small, too soon: antiretroviral prophylaxis and treatment in preterm and low birth weight infants
Too small, too soon: antiretroviral prophylaxis and treatment in preterm and low birth weight infants Mark Mirochnick, MD Boston University School of Medicine, Boston, MA, USA Full Term Full Term 34 wks
More informationList of Optimal Paediatric Formulations. Marianne Gauval (CHAI) IAS-ILF Round table Geneva, Switzerland 26 November 2013
List of Optimal Paediatric Formulations Marianne Gauval (CHAI) IAS-ILF Round table Geneva, Switzerland 26 November 2013 1 History of development of treatment options for children Adult tablets Syrups and
More informationART and Prevention: What do we know?
ART and Prevention: What do we know? Biomedical Issues Trip Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Cornell Medical College New York City ART for Prevention:
More informationSeparate clinical trials for HIV- HCV coinfected patients are NOT a necessity. Patrick Ingiliz, Berlin
Separate clinical trials for HIV- HCV coinfected patients are NOT a necessity Patrick Ingiliz, Berlin Back in the days when HCV genotype 1 was the problem SVR (%) 100 90 80 70 60 50 40 30 20 10 0 35% PRESCO
More informationQ&A for submission of applications for prequalification of Zinc Sulfate tablets and Zinc Sulfate oral liquid (solution)
Q&A for submission of applications for prequalification of Zinc Sulfate tablets and Zinc Sulfate oral liquid (solution) This document should not be treated as a comprehensive guideline; it serves as a
More informationHIV Drugs and the HIV Lifecycle
HIV Drugs and the HIV Lifecycle Together, we can change the course of the HIV epidemic one woman at a time. #onewomanatatime #thewellproject All HIV drugs work by interrupting different steps in HIV's
More informationNON-OCCUPATIONAL POST EXPOSURE PROPHYLAXIS IN HIV PREVENTION. Jason E. Vercher, PA-C, AAHIVM
NON-OCCUPATIONAL POST EXPOSURE PROPHYLAXIS IN HIV PREVENTION Jason E. Vercher, PA-C, AAHIVM Disclosures No disclosures to report Learning Objectives q Identify Individuals who would benefit from non-occupational
More informationThe Annotated Bibliography of the UCSF HIV Solid Organ Transplantation Project. ARV Dosing in End Stage Renal Disease
The Annotated Bibliography of the UCSF HIV Solid Organ Transplantation Project ARV Dosing in End Stage Renal Disease 1. Jayasekara, D., Aweeka, F. T., Rodriguez, R., Kalayjian, R. C., Humphreys, M. H.,
More informationSources and Prices of Medicines for Children.
Sources and Prices of Medicines for Children. Consultation on Priority Essential Medicines for Child Survival 6th-7th September, 2010 Copenhagen, Denmark 1 Sources and Prices of Selected Medicines for
More informationAntiretroviral Pharmacovigilance Training Course. Dar es Salaam, United Republic of Tanzania
Antiretroviral Pharmacovigilance Training Course Dar es Salaam, United Republic of Tanzania 23 rd 28 th November 2009 SAFETY MONITORING OF ARVs IN GHANA NATIONAL AIDS/STI CONTROL PROGRAMME FOOD AND DRUGS
More informationCOMPREHENSIVE ANTIRETROVIRAL TABLE: ADULT DOSING, DOSAGE FORM MODIFICATIONS, ADVERSE REACTIONS and INTERACTION POTENTIAL
Generic Name COMPREHENSIVE ANTIRETROVIRAL TABLE: NUCLOESIDE/TIDE REVERSE TRANSCRIPTASE INHIBITORS (N(t)RTIs) Abacavir ABC (Ziagen) Didanosine ddi (Videx EC) Emtricitabine FTC (Emtriva) Lamivudine 3TC (Epivir)
More informationPrequalification Programme Bioequivalence Assessment Update. Dr. John Gordon
Prequalification Programme Bioequivalence Assessment Update Dr. John Gordon WHO Prequalification of Medicines Programme 3 rd Meeting with Manufacturers of FPPs and APIs Overview Review of commonly used
More informationALABAMA S ADAP FORMULARY OFFERS 117 MEDICATIONS
ALABAMA S ADAP FORMULARY OFFERS 117 MEDICATIONS - 2014 Alabama s ADAP formulary offers a minimum of one medication from each HIV antiretroviral class approved by the U.S. Food and Drug Administration (FDA).
More informationGPRM - Global Price Reporting Mechanism December Transaction prices for Antiretroviral Medicines and HIV Diagnostics from 2008 to October 2010
Transaction prices for Antiretroviral Medicines and HIV Diagnostics from 2008 to October 2010 A summary report from the Global Price Reporting Mechanism Contents Background and Methods................................
More informationA Call to Action Children The missing face of AIDS
A Call to Action Children The missing face of AIDS OVERVIEW OF PRESENTATION Introduction : lessons learnt Availability ; implications of making paediatric formulations available Remaining challenges in
More informationUNICEF/WHO Technical Consultation: IMPROVING ACCESS TO APPROPRIATE PAEDIATRIC ARV FORMULATIONS. November 3-4, WHO Headquarters, Geneva, EB Room
UNICEF/WHO Technical Consultation: IMPROVING ACCESS TO APPROPRIATE PAEDIATRIC ARV FORMULATIONS November 3-4, 2004 WHO Headquarters, Geneva, EB Room Summary Background In 2003, more than 5 million people
More informationClinical Commissioning Policy: Use of cobicistat (Tybost ) as a booster in treatment of HIV positive adults and adolescents
Clinical Commissioning Policy: Use of cobicistat (Tybost ) as a booster in treatment of HIV positive adults and adolescents 1 Clinical Commissioning Policy: Use of cobicistat (Tybost ) as a booster in
More informationTransaction Prices for Antiretroviral Medicines from 2010 to Global Price Reporting Mechanism
SUMMARY report AIDS medicines and diagnostics service Transaction Prices for Antiretroviral Medicines from 2010 to 2013 Global Price Reporting Mechanism December 2013 AIDS medicines and diagnostics service
More informationComprehensive Guideline Summary
Comprehensive Guideline Summary Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents AETC NRC Slide Set Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and
More informationHIV medications HIV medication and schedule plan
Living with HIV (human immunodeficiency virus) It may be scary to find out that you re HIV-positive or have AIDS. Coping with this news may be difficult. Although HIV is a serious infection, people with
More information25 October 2005 INTRODUCTION
Relative market share of different antiretroviral compounds in low and middle income countries in 2004 and 2005: an analysis of 2 public domain data bases Prepared by the AIDS Medicines and Diagnostics
More informationRegistration and Quality Assurance of ARVs and other Essential Medicines in Namibia
Registration and Quality Assurance of ARVs and other Essential Medicines in Namibia October 2014 September 2015 Registration and Quality Assurance of ARVs and other Essential Medicines in Namibia Nasser
More informationHIV Update Objectives. Epidemiology. Epidemiology, Transmission and Natural History. Transmission Risk by Exposure. Transmission 9/29/2014
Objectives HIV Update 2014 Jay Sizemore, MD, MPH Medical Director Chattanooga CARES Assistant Professor UTCOM Chattanooga 2October 2014 Review HIV epidemiology and screening/testing guidelines Discuss
More informationORAL ANTIRETROVIRAL ADMINISTRATION: INFORMATION ON CRUSHING AND LIQUID DRUG FORMULATIONS
ORAL ANTIRETROVIRAL ADMINISTRATION: INFORMATION ON CRUSHING AND LIQUID DRUG FORMULATIONS Combination Products: Atripla (efavirenz/ emtricitabine/ tenofovir) no Consider use of Truvada tabs and efavirenz
More informationJohn Amis/AP Images for AIDS. Healthcare Foundation
John Amis/AP Images for AIDS Healthcare Foundation Sofosbuvir Bought in 2011 by Gilead for 11 billion: "a huge and risky bet on the next generation of hepatitis C treatments" (Reuters) Patent situation:
More informationA Fatal Imbalance. Tropical diseases: 18 new drugs (incl. 8 for malaria) 1.3% 21 new drugs for neglected diseases. Tuberculosis: 3 new drugs
ADDRESSING GAPS IN INNOVATION FOR NEGLECTED PATIENTS: DNDI ANDPEDIATRIC HIV/AIDS Rachel Cohen, Regional Executive Director, DNDi North America Proposals for a Global Innovation System that Responds to
More informationPage 1 of 5 ENLGLISH / ESPAÑOL / PORTUGUÉS / FRANÇAIS Share 3 Drug Chart for HIV Treatment CURRENT EDITION ABOUT SENSE BACK ISSUES MSMGF HOME CONTACT US There are a number of antiretroviral (ARV) medications
More informationADAP Monitoring Provider Prescribing Patterns. Amanda Bowes, NASTAD Christine Rivera and Dr. Charles Gonzalez, NYS AIDS Institute
ADAP Monitoring Provider Prescribing Patterns Amanda Bowes, NASTAD Christine Rivera and Dr. Charles Gonzalez, NYS AIDS Institute WEBINAR ETIQUETTE All questions or comments can be shared either via the
More informationMedication Errors Focus on the HIV-Infected Patient
Medication Errors Focus on the HIV-Infected Patient Nimish Patel, Pharm.D., Ph.D., AAHIVP Associate Professor Albany College of Pharmacy & Health Sciences I do not have any conflict of interest in relation
More informationWHO Global Price Reporting Mechanism the importance of data registration for the regulation of antiretrovirals (ARV) and access to treatment
WHO Global Price Reporting Mechanism the importance of data registration for the regulation of antiretrovirals (ARV) and access to treatment Boniface Dongmo Nguimfack HIV/Technology and Commodities 1 AMDS
More informationDr Alan Winston. Imperial College Healthcare NHS Trust London. 7-8 October 2010, Queen Elizabeth II Conference Centre, London.
BHIVA AUTUMN CONFERENCE 2010 Including CHIVA Parallel Sessions Dr Alan Winston Imperial College Healthcare NHS Trust London 7-8 October 2010, Queen Elizabeth II Conference Centre, London BHIVA AUTUMN CONFERENCE
More informationAddressing Pediatric Needs of the Most Neglected: next steps
Addressing Pediatric Needs of the Most Neglected: next steps An updated overview of DNDi Pediatric Focus Nathalie Strub Wourgaft (Medical Director) Janice Lee (HIV Pediatric Clinical Manager) A Fatal Imbalance
More informationAppropriate Use & Safety Edits
Appropriate Use & Safety Edits Envolve Pharmacy Solutions provides a variety of safety edits to promote the use of the right medication, in the right patient, at the right time. These edits are routinely
More informationElements for a Public Summary. Overview of disease epidemiology. Epidemiology of the disease
VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Epidemiology of the disease Cytomegalovirus is found throughout all geographic locations and socioeconomic groups, and infects
More informationHIV and the Central Nervous System Impact of Drug Distribution Scott L. Letendre, MD. Professor of Medicine University of California, San Diego
HIV and the Central Nervous System Impact of Drug Distribution Scott L. Letendre, MD Professor of Medicine University of California, San Diego Disclosures Grant/research support Abbvie Gilead Sciences
More informationActualización y Futuro en VIH
Actualización y Futuro en VIH Dr. Santiago Moreno Servicio de Enfermedades Infecciosas Hospital U. Ramón y Cajal. Universidad de Alcalá. IRYCIS. Madrid Agenda Control of the HIV-epidemic Coinfections Antiretroviral
More informationEMTRICITABINE AND TENOFOVIR TABLETS
September 2010 RESTRICTED EMTRICITABINE AND TENOFOVIR TABLETS Draft proposal for The International Pharmacopoeia (September2010) REVISED DRAFT FOR COMMENT This document was provided by a quality control
More informationClinical Pharmacy in Malaysia: Past,Present and Future
Clinical Pharmacy in Malaysia: Past,Present and Future Noraini bt Mohamad Senior Principal Assistant Director Pharmaceutical Services Division Ministry of Health, Malaysia 11.10.2014 VISION, MISSION
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 9 May 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 9 May 2012 EDURANT 25 mg film-coated tablets B/30 (CIP code: 219 472-9) Applicant: JANSSEN-CILAG rilpivirine ATC code
More informationSelected Issues in HIV Clinical Trials
Selected Issues in HIV Clinical Trials Judith S. Currier, M.D., MSc Professor of Medicine Division of Infectious Diseases University of California, Los Angeles Issues Evolving Global and Domestic Epidemic
More informationCategory and Product-level Procurement and Delivery Planning Guide
Category and Product-level Procurement and Delivery Planning Guide Indicative Lead Times 3 July 2018 This document lays out indicative lead-times for planning purposes for key health products for the Global
More information104 MMWR December 17, 2004
104 MMWR December 17, 2004 TABLE 8. Substantial pharmacokinetic drug-drug interactions for drugs used in the treatment of opportunistic Drugs Interacting with Mechanism/effects Recommendations Acyclovir
More informationThe Global Health Impact Index
The Global Health Impact Index Ranking Explanation Reference Table Drug Abbreviation Drug Name 1. AL 1. Artemether-Lumefantrine 2. AS+AQ 2. Artesunate + Amodiaquine 3. AS+MQ 3. Artesunate + Mefloquine
More informationreductions Untangling the web of price reductions: eligibility pricecountries company price countries price
company price countries reductions pricecountries price eligibility reductions Untangling the web of price reductions: a pricing guide for the purchase of ARVs for developing countries 1st December 2003
More informationUNICEF/Malawi/2015/Schermbrucker. policy brief 2016 UPDATE
UNICEF/Malawi/2015/Schermbrucker policy brief IATT PAEDIATRIC ARV FORMULARY AND LIMITED-USE LIST: 2016 UPDATE BACKGROUND Delivery of antiretroviral treatment (ART) to children living with HIV is associated
More information